Search Results for: 68

Synthetic Biologics Reports 2020 Third Quarter Operational Highlights and Financial Results

— Received Notice from the FDA that the SYN-004 (ribaxamase) Phase 1b/2a Clinical Program in Adult Allogeneic HCT Recipients May Proceed as Planned; Trial Commencement Anticipated in Q1 2021 — — Received Study-May-Proceed Letter from the FDA Supporting a Phase 1 Single Ascending Dose Study of SYN-020 IAP; Phase 1 Study to Support Development of

Synthetic Biologics Reports 2020 Third Quarter Operational Highlights and Financial Results Read More »

Synthetic Biologics Reports 2020 Second Quarter Operational Highlights and Financial Results

— Announced FDA Clearance of IND Application for SYN-020 Intestinal Alkaline Phosphatase (IAP) — — Signed Option License Agreement with Massachusetts General Hospital to Develop SYN-020 to Treat and Prevent Metabolic and Inflammatory Diseases Associated with Aging — — Enrollment in the Phase 2b Investigator-Sponsored Clinical Trial of SYN-010 Has Recommenced Following COVID-19-Related Postponement —

Synthetic Biologics Reports 2020 Second Quarter Operational Highlights and Financial Results Read More »

Synthetic Biologics Reports 2019 Year End Operational Highlights and Financial Results

— Received FDA Guidance Following Type-C Meeting to Conduct a Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic HCT Recipients; Enrollment Expected in Q2 2020 — — Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010 for the Treatment of IBS-C — Conference Call Today at 4:30 p.m. (ET) — ROCKVILLE, Md.,

Synthetic Biologics Reports 2019 Year End Operational Highlights and Financial Results Read More »

Synthetic Biologics Receives FDA Guidance at Type C Meeting for SYN-004 (ribaxamase) Phase 1b/2a Clinical Trial in Allogeneic HCT Recipients

ROCKVILLE, Md., Jan. 7, 2020 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced the receipt of official meeting minutes from the U.S. Food and Drug Administration (FDA) following a Type C

Synthetic Biologics Receives FDA Guidance at Type C Meeting for SYN-004 (ribaxamase) Phase 1b/2a Clinical Trial in Allogeneic HCT Recipients Read More »

Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan

ROCKVILLE, Md., Nov. 27, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced it has received written communication from NYSE American LLC (the “Exchange”), the Company’s current listing exchange, stating

Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan Read More »

Synthetic Biologics Reports Third Quarter 2019 Operational Highlights and Financial Results

— Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C — — Conference Call Today, November 4, 2019, at 4:30 p.m. (EST) — ROCKVILLE, Md., Nov. 4, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent

Synthetic Biologics Reports Third Quarter 2019 Operational Highlights and Financial Results Read More »